Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Barca-Hernando, M; Munoz-Martin, AJ; Rios-Herranz, E; Garcia-Escobar, I; Beato, C; Font, C; Oncala-Sibajas, E; Revuelta-Rodriguez, A; Areses, MC; Rivas-Jimenez, V; Ballaz-Quincoces, A; Moreno-Santos, MA; Lopez-Saez, JB; Gallego-Gallego, I; Elias-Hernandez, T; Asensio-Cruz, MI; Chasco-Eguilaz, L; Garcia-Gonzalez, G; Estevez-Garcia, P; Marin-Barrera, L; Otero-Candelera, R; Lopez-Ruz, S; Lima-Alvarez, J; Sanchez-Diaz, JM; Real-Dominguez, M; Borrego-Delgado, MC; Marin-Romero, S; Jara-Palomares, L.

Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis

Cancers. 2021; 13(11): Nº de citas: 9 [doi:10.3390/cancers13112517]

Gonzalez-Senac, NM; Mayordomo-Cava, J; Macias-Valle, A; Aldama-Marin, P; Gonzalez, SM; Arnes, MLC; Jimenez-Gomez, LM; Vidan-Astiz, MT; Serra-Rexach, JA.

Colorectal Cancer in Elderly Patients with Surgical Indication: State of the Art, Current Management, Role of Frailty and Benefits of a Geriatric Liaison

International Journal of Environmental Research and Public Health. 2021; 18(11): Nº de citas: 27 [doi:10.3390/ijerph18116072]

Garcia-Martin, E; Escudero-Vilaplana, V; Fox, B; Collado-Borrell, R; Marzal-Alfaro, B; Sanchez-Isac, M; Solano-Garzon, ML; del Val, RG; Cano-Gonzalez, JM; de Lucas, NP; Bravo-Guillen, AI; Valero-Salinas, J; Gonzalez-Haba, E; Sanjurjo, M; Martin, M.

Aggressiveness of end-of-life cancer care: what happens in clinical practice?

SUPPORTIVE CARE IN CANCER. 2021; 29(6): 3121-3127 Nº de citas: 8 [doi:10.1007/s00520-020-05828-9]

Garcia-Escobar, I; Brozos-Vazquez, E; Abad, DG; Martinez-Marin, V; Pachon, V; Martin, AJM; Canc Thrombosis Sect Spanish.

Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence

Clinical & Translational Oncology. 2021; 23(6): 1034-1046 Nº de citas: 8 [doi:10.1007/s12094-020-02506-4]

Bellmunt, J; Esteban, E; Muro XGD; Sepulveda, JM; Maroto, P; Gallardo, E; Alba AGD; Etxaniz, O; Guix, M; Larriba JLG; Arranz, JA; Redrado, M; Calvo, A.

Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

European Urology Oncology. 2021; 4(3): 502-505 Nº de citas: 5 [doi:10.1016/j.euo.2019.07.014]

Escudero-Vilaplana, V; Collado-Borrell, R; Villanueva-Bueno, C; Alvarez, R; Herranz, A; Sanjurjo, M.

Acute pancreatitis in a patient treated with imatinib and gefitinib

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021; 27(4): 980-983 Nº de citas: 3 [doi:10.1177/1078155220949639]

Taboada AGM; Lominchar PL; Roman LM; García-Alfonso P; Martin AJM; Rodriguez JAB; Pascual JMA.

Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades.

Annals of Hepato-Biliary-Pancreatic Surgery. 2021; 25(2): 179-191 Nº de citas: 17 [doi:10.14701/ahbps.2021.25.2.179]

Loibl, S; Marme, F; Martin, M; Untch, M; Bonnefoi, H; Kim, SB; Bear, H; McCarthy, N; Olive, MM; Gelmon, K; Garcia-Saenz, J; Kelly, CM; Reimer, T; Toi, M; Rugo, HS; Denkert, C; Gnant, M; Makris, A; Koehler, M; Huang-Bartelett, C; Frean, MJL; Colleoni, M; Werutsky, G; Seiler, S; Burchardi, N; Nekljudova, V; von Minckwitz, G.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(14): 1518-1530 Nº de citas: 273 [doi:10.1200/JCO.20.03639]

Alvarez, YE; Bataller, RD; Altozano, JP; Martinez, SR; Alvarez, AS; Cordellat, AB; Vazquez, EB; Jaime, JC; Escobar, IG; Zambrano, CB.

SEOM clinical guidelines for anaemia treatment in cancer patients (2020)

Clinical & Translational Oncology. 2021; 23(5): 931-939 Nº de citas: 21 [doi:10.1007/s12094-021-02580-2]

Verso, M; Munoz, A; Bauersachs, R; Huisman, MV; Mandala, M; Vescovo, G; Becattini, C; Agnelli, G.

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

EUROPEAN JOURNAL OF CANCER. 2021; 148: 371-381 Nº de citas: 51 [doi:10.1016/j.ejca.2021.02.026]

Escobar-Alvarez, Y; de Castro-Carpeno, J; Feyjoo, M; Martin-Algarra, S.

Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy

Journal of Healthcare Quality Research. 2021; 36(3): 142-149 [doi:10.1016/j.jhqr.2021.01.001]

Majem, M; Manzano, JL; Marquez-Rodas, I; Mujika, K; Munoz-Couselo, E; Perez-Ruiz, E; de la Cruz-Merino, L; Espinosa, E; Gonzalez-Cao, M; Berrocal, A.

SEOM clinical guideline for the management of cutaneous melanoma (2020)

Clinical & Translational Oncology. 2021; 23(5): 948-960 Nº de citas: 19 [doi:10.1007/s12094-020-02539-9]

del Alba, AG; Mendez-Vidal, MJ; Vazquez, S; Castro, E; Climent, MA; Gallardo, E; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Arranz, JA.

SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)

Clinical & Translational Oncology. 2021; 23(5): 969-979 Nº de citas: 22 [doi:10.1007/s12094-021-02561-5]

Gomez-Espana, MA; Montes, AF; Garcia-Carbonero, R; Mercade, TM; Maurel, J; Martin, AM; Pazo-Cid, R; Vera, R; Carrato, A; Feliu, J.

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

Clinical & Translational Oncology. 2021; 23(5): 988-1000 Nº de citas: 40 [doi:10.1007/s12094-021-02573-1]

Martin, M; Mayer, IA; Walenkamp, AME; Lapa, C; Andreeff, M; Bobirca, A.

At the bedside: Profiling and treating patients with CXCR4-expressing cancers

JOURNAL OF LEUKOCYTE BIOLOGY. 2021; 109(5): 953-967 Nº de citas: 24 [doi:10.1002/JLB.5BT1219-714R]

Ferre, AD; Alvarez, RA; Herraez, AC; Jurado, JC; Gonzalez, AE; Martin-Broto, J; Marin, VM; Vega, AM; Garcia, AS; Morales, CV.

SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

Clinical & Translational Oncology. 2021; 23(5): 922-930 Nº de citas: 34 [doi:10.1007/s12094-020-02534-0]

Sastre, J; Garcia-Alfonso, P; Vieitez, JM; Cano, MT; Rivera, F; Reina-Zoilo, JJ; Salud-Salvia, A; Quintero, G; Robles-Diaz, L; Safont, MJ; La Casta, A; Gil, S; Polo, E; Asensio-Martinez, E; Garcia-Paredes, B; Lopez, RL; Guillot, M; Valladares-Ayerbes, M; Aranda, E; Diaz-Rubio, E.

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and < 3 baseline circulating tumour cells: the randomised phase II VISNU-2 study

ESMO Open. 2021; 6(2): 100062-100062 Nº de citas: 11 [doi:10.1016/j.esmoop.2021.100062]

Hecht, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY.

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(10): 1108 Nº de citas: 84 [doi:10.1200/JCO.20.02232]